A Phase I Study of BAFF CAR-T Cells (LMY-920) for Treatment of Systemic Lupus Erythematosus
Latest Information Update: 09 Jun 2025
At a glance
- Drugs LMY-920 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Luminary Therapeutics
Most Recent Events
- 03 Jun 2025 Planned primary completion date changed from 15 Jan 2026 to 15 Apr 2026.
- 03 Jun 2025 Status changed from not yet recruiting to recruiting.
- 21 Oct 2024 Planned End Date changed from 15 Apr 2026 to 15 Jun 2026.